Given the high PD-L1 expression observed in his MPE and the proven efficacy of ivonescimab monotherapy in PD-L1-positive NSCLC (25), he opted for ivonescimab monotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.